International Journal of Pharmaceutical Investigation logo
Submit
International Journal of Pharmaceutical InvestigationACADEMIC PUBLISHING
Article

Docking Sites of Indole Derivative on Mitogen-Activated Protein Kinase (MAPK) Inhibitor (PDB ID- 1A9U) against Inflammation

1★, 1, 1, 1, 1★ Corresponding author

  1. 1Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy Pravaranagar, Tal-Rahata, Ahmednagar, Maharashtra, INDIA.

CORRESPONDENCE

Rohit Jaysing Bhor

Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy Pravaranagar, Tal-Rahata, Ahmednagar, Maharashtra, INDIA.

rohit.bhor69@gmail.com

Received: 18-08-2023; Revised: 24-09-2023; Accepted: 22-10-2023.

Volume 14, Issue 1 · pp. 172-179 · 2023 · DOI: 10.5530/ijpi.14.1.22

ABSTRACT

Background: The serine/threonine kinase p38 Mitogen-Activated Protein (MAP) kinase is one of the most well studied kinases in the inflammatory process. The goal of this study was to see how a p38 MAP Kinase inhibitor (PDB ID- 1A9U) affected the activity of a p38 MAP kinase implicated in inflammation. "Inflammation is a common feature of age-related neurodegenerative diseases in the Central Nervous System (CNS)." The p38 Mitogen-Activated Protein Kinase (MAPK) pathway regulates the synthesis of IL-1 and TNF.Materials and Methods: The study focused on molecular docking and ADME of the relationships that exist between [4-amino-3-(1H-indol-1-yl) phenyl] (4-hydroxyphenyl) methanone derivatives and p38 Mitogen-Activated Protein (MAP) kinase. Inhibition of p38 Mitogen-Activated Protein (MAP) kinase pathway, a series of [4-amino3-(1H-indol-1-yl) phenyl] (4-hydroxyphenyl) methanone derivations were developed and evaluated in silico. The designed composites' medicine-likeness packets were predicted.Results: According to molecular docking experiments, all composites had improved interactions with the target protein and may be powerful drugs. The developed [4-amino-3-(1H-indol-1-yl) phenyl] (4-hydroxyphenyl) methanone analogues may be more effective and safer anti-inflammatory medicines.Conclusion: According to the findings of this investigation, p38 MAPK inhibitors alone are a unique therapeutic target for inflammatory disorders. p38 Mitogen-Activated Protein (MAP) Kinase is a critical serine/threonine kinase that has been well studied in the inflammatory process.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Bhor, R. J., Agale, A. C., Sitaram, G. M., Navnath, M. D., & Sunil, W. S. (2023). Docking Sites of Indole Derivative on Mitogen-Activated Protein Kinase (MAPK) Inhibitor (PDB ID- 1A9U) against Inflammation. International Journal of Pharmaceutical Investigation, 14(1), 172-179. https://doi.org/10.5530/ijpi.14.1.22

    Copyright and licence

    © 2023 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0